acorda posts
FeedPosted Oct 15th 2009 4:00PM by Jon Ogg (RSS feed)

Today was a multifaceted news day. There was
tame inflation and a
better jobs report, but oil went through the roof as there was a
big draw down in gasoline inventory and weak refinery trends. The earnings reports are now coming on in full force.
Here were today's unofficial closing bell levels:
Dow 10,062.94 +47.08 (0.47%)
S&P 500 1,096.56 +4.54 (0.42%)
Nasdaq 2,173.29 +1.06 (0.05%)
Top 10 Analyst CallsTop Stock RumorsContinue reading Closing Bell: DJIA 10K again, really again (GS, C, AXP, VLO, DRWI, ACOR)
Posted Mar 12th 2008 12:10PM by Eric Buscemi (RSS feed)
Filed under: Analyst reports, Chipotle Mexican Grill'A' (CMG), Analyst initiations
MOST NOTEWORTHY: Chipotle Mexican Grill, Micrus Endovascular and Acorda Therapeutics were today's noteworthy initiations:
- Jefferies expects the quality gap between Chipotle Mexican Grill (NYSE: CMG) and its peers will become more apparent in a weakening consumer environment. The firm started shares with a Buy rating and $110 target.
- Micrus Endovascular (NASDAQ: MEND) was initiated with an Outperform rating and $20 target at Barrington, citing the company's strong product line, improving salesforce, leading market share position and their expectation for continued strong transition from clipping to coiling.
- Acorda Therapeutics (NASDAQ: ACOR) was assumed with an Overweight rating at JP Morgan, as they believe the company's Fampridine-SR for multiple sclerosis is a $500M + opportunity
OTHER INITIATIONS:
Posted Oct 15th 2007 11:00AM by Eric Buscemi (RSS feed)
Filed under: Analyst reports, Analyst upgrades and downgrades
MOST NOTEWORTHY: Banco Santander, Acorda Therapeutics, Agruim, Annaly Capital and ImmunoGen were today's noteworthy upgrades:
- UBS upgraded shares of Banco Santander (NYSE: STD) to Buy from Neutral as they expect the acquisition of ABN Amro Holding NV (NYSE: ABN) assets in Brazil and Italy to boost earnings in 2008 and 2009.
- Friedman Billings added Acorda Therapeutics (NASDAQ: ACOR) to its Top Picks List, as they have confidence in fampridine-SR's safety profile.
- Agrium (NYSE: AGU) was upgraded to Sector Outperformer from Sector Performer at CIBC on valuation, as they believe the outlook for wholesale and retail is robust with all three nutrients at historical high levels.
- Annaly Capital Management (NYSE: NLY) was upgraded to Buy from Neutral at UBS, citing likely further FED cuts, benefits from recent secondary, and BVPS growth.
- RBC Capital upgraded shares of ImmunoGen (NASDAQ: IMGN) to Outperform from Sector Perform based on valuation, growing pipeline, valuable technology platform, and potential as an acquisition candidate.
OTHER UPGRADES:
Posted Feb 21st 2007 11:32AM by Kevin Shult (RSS feed)
Filed under: Before the bell, , Coach Inc (COH), Analyst initiations

MOST NOTEWORTHY: Acorda Therapeutics Inc (ACOR) and Coach, Inc (COH) were some of today's most notable initiations:
- Morgan Joseph started Acorda Therapeutics Inc (NASDAQ: ACOR) with a Sell rating and $15 target citing seizure rates for Fampridine-SR and limited efficacy for its rating.
- Coach, Inc (NYSE: COH) was started at Soleil with a Buy rating and $58 target; the firm believes continuing market share gains should create a long-term EPS growth rate of 23%.
OTHER INITIATIONS:
- Morgan Stanley initiated Time Warner Cable (OTC: TWCA) with an Equal Weight rating.
- Raymond James started Legacy Reserves LP (NASDAQ: LGCY) with an Outperform rating and $27 target.
- Wedbush initiated Avaya Inc (NYSE: AV) with a Hold rating and $14 target.
- Nollenberger initiated Rudolph Technologies Inc (NASDAQ: RTEC) with a Buy rating and $26 target, citing valuation.
- Precision Drilling Trust (NYSE: PDS) was initiated at CIBC with a Sector Performer rating.
- Lehman Brothers started Polo Ralph Lauren Corp (NYSE: RL) with an Overweight rating and $100 target.
- Bank of America reinstated The Nasdaq Stock Market Inc (NASDAQ: NDAQ) with a Neutral rating and $33 target.
Analyst summaries provided by TheFlyOnTheWall.com (subscription required).